secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055872
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024
--------------------------------------------------------------------------------

- Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).
- Initial Phase 2 TouCAHn data: atumelnant shows rapid, profound reductions in androstenedione and 17-hydroxyprogesterone in classic congenital adrenal hyperplasia.
- Phase 1b/2a data on atumelnant in ACTH-dependent Cushing's shows first evidence of rapid, sustained cortisol reductions.
- Phase 3 PATHFNDR-2 paltusotine data in medically untreated acromegaly patients to be presented; PATHFNDR-1 patient-reported symptoms and long-term safety also featured.
- Crinetics plans to submit paltusotine NDA later in 2024; CEO cites major milestone for pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024055872/0000950170-24-055872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024055872/crnx-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer